Browse articles from EyeWorld.org related to gene therapy. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Results from Phase 1 clinical trial of intranasal glaucoma drug ➤ Phase 3 clinical trial of new ophthalmic corticosteroid nanoemulsion ➤ Pharmaceutical company expands gene therapy pipeline ➤ Companies enter agreement to develop next-generation decision support software ➤ Study: Association between caffeine intake and glaucoma
➤ Early termination of study evaluating Beovu ➤ NDA resubmitted to FDA for investigational macular edema treatment ➤ First peer-reviewed paper on visual recovery in a blind patient treated with optogenetic therapy ➤ Study: New riboflavin formulation enhances transepithelial crosslinking ➤ Enrollment complete for blepharitis trial ➤ Companies partner to develop human-induced pluripotent stem cell-derived therapies for ocular diseases ➤ ASCRS events
➤ Investigating adjuvant therapy to DSO for Fuchs ➤ FDA approves loteprednol etabonate ophthalmic gel ➤ Pilot study: Photobiomodulation improves BCVA in patients with dry AMD ➤ Positive interim data in trial for gene therapy for GA ➤ Four Phase 3 studies of faricimab show up to 4-month treatment intervals for DME and wet AMD
➤ 2021 ASCRS Annual Meeting update ➤ FDA approves new monofocal IOL ➤ First patient dosed in Phase 2 trial for investigational DED therapy ➤ Phase 2a trial initiated for add-on wet AMD therapy
➤ Success with first-in-human implant of new artificial cornea ➤ Launch of first longitudinal study for home OCT ➤ Enrollment complete for study evaluating treatment for Leber congenital amaurosis 10 ➤ Phase 1/2a trial for wet AMD treatment with suprachoroidal injection begins enrollment ➤ Fast Track designation issued for investigational dry AMD therapy